Piper Sandler Upgrades Omnicell: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Piper Sandler has upgraded its rating of Omnicell (NASDAQ:OMCL) to Overweight with a new price target of $39.00, down from $70.00. Omnicell's shares are currently trading up 1.81% at $29.77 per share. A move to $39.00 would account for a 31.0% increase from the current share price. Omnicell provides automation and business analytics software for healthcare providers, generating the majority of its revenue in the United States.
November 03, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has upgraded Omnicell to Overweight and lowered its price target to $39.00. This could lead to a potential 31.0% increase in the stock price.
The upgrade by Piper Sandler is a positive signal for Omnicell. The new price target, despite being lower than the previous one, still represents a significant potential upside from the current trading price. This could attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100